Partner | Corporate and Commercial, Corporate Restructuring, Regulatory Practice
- T: +91 120 479 1000
- E: Write to me
education
- LL.B., D.D.U. Gorakhpur University ( Gold Medalist) (2005)
- B.Com.,D.D.U. Gorakhpur University (2002)
Atul Pandey is a Partner in the Corporate team. Prior to joining Khaitan & Co, he was a senior member of the corporate team at Fox Mandal & Co, Delhi. He has been advising on corporate and commercial issues, regulatory matters including under the Foreign Exchange Management Act, 1999, FDI Policy and obtaining approvals, mergers & acquisitions (domestic and cross-border), domestic and cross-border joint ventures, capital markets, private equity investment, labour & employment and trade laws, direct & indirect tax, dispute resolution, banking & finance, and other areas of corporate law practice.
Professional Affiliations
- Bar Council of Delhi
Representative Matters
Atul Pandey has represented and advised the following clients
GlaxoSmithKline Plc (GSK)
Advised and obtained FIPB approval in relation to a major three-part global transaction between GSK and Novartis AG (Novartis), pursuant to which GSK is forming a consumer health joint venture with Novartis, while at the same time buying Novartis vaccines business and divesting its cancer drugs portfolio to Novartis. The three inter-conditional deals are worth over USD 20 billion.
MacRitchie Pte Ltd (Temasek entity)
Advised on the transaction and obtained FIPB approval in respect of foreign direct investment and proposed issue and allotment of compulsory convertible preference shares representing 49.99% of the fully diluted post issue share capital of MakeSense Technologies Limited, on a private placement basis to MacRitchie Investments Pte Ltd, a wholly owned indirect subsidiary of Temasek Holdings (Private) Limited, Singapore.
Mitsui & Co. (Asia Pacific) Pte Ltd
Advised on the transaction and obtained DIPP clarification/approval in respect of proposed investment in Keimed Private Limited, an Indian company engaged exclusively in the business of wholesale trading of pharmaceutical and medical goods, and with specific reference to whether wholesale trading of pharmaceutical products would fall within the automatic route or would it require approval from the FIPB.
Ryohin Keikaku Co., Ltd, Japan and Reliance Brands Ltd
Advised on setting up a joint venture and obtained approval from the DIPP/FIPB/DEA on behalf of Ryohin Keikaku Co., Ltd, Japan, for the proposed foreign direct investment in single brand retail sector in India by way of subscribing upto 51% equity shares of a joint venture along with joint venture partner Reliance Brands Limited.
Natco Pharma Limited
Advised on the QIP process transaction and obtained regulatory approval from the FIPB/DIPP/DEA for allotment of securities compliant with the FDI Policy by Natco Pharma to Qualified Institutional Buyers, pursuant to Chapter VIII (QIP) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009.
Lupin Limited
Advised on various issues connected with FDI policy and obtained regulatory guidance clarification from the RBI in respect of ESOPs granted/ issue of shares under ESOPs to non-resident employees.
Meher Investments Private Limited
Advised on the transaction and submitted applications to regional branches of RBI- in connection with merger/amalgamation of several NBFC Companies.
Dharampal Satyapal Group
Advised on the transaction and obtained regulatory approval from the RBI for winding up of DS Guinea, wholly owned overseas subsidiary, in Africa and for write off of the capital and loan granted to it by the parent company.
Jindal Steel & Power
Advised on the transaction and obtained regulatory approval from RBI for undertaking financial commitment by Jindal Steel & Power Limited by way of issue of bank guarantee in form of ‘Stand by Letter of Credit’ on behalf of JSPL’s overseas wholly owned subsidiary, Jindal Steel & Power (Mauritius) Limited and provision of cash collateral.
Publications
Ergo Newsflash
Ergo Update
Article
Article
Article
